We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
+8.42%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$353M
AUM Growth
-$134M
(-28%)
Cap. Flow
-$158M
Cap. Flow
% of AUM
-44.72%
Top 10 Holdings %
Top 10 Hldgs %
53.01%
Holding
85
New
13
Increased
11
Reduced
25
Closed
34
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Henry Schein
HSIC
|
+$15.5M |
| 2 |
Cigna
CI
|
+$8.74M |
| 3 |
AdaptHealth
AHCO
|
+$8.55M |
| 4 |
Viatris
VTRS
|
+$8.32M |
| 5 |
UnitedHealth
UNH
|
+$7.97M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Labcorp
LH
|
+$19.6M |
| 2 |
HOLX
Hologic
HOLX
|
+$18.4M |
| 3 |
Quest Diagnostics
DGX
|
+$17.7M |
| 4 |
LMNX
Luminex Corp
LMNX
|
+$15.3M |
| 5 |
RadNet
RDNT
|
+$12.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.4% |
| 2 | Consumer Staples | 5.19% |
| 3 | Miscellaneous | 2.47% |
| 4 | Consumer Discretionary | 1.58% |
| 5 | Technology | 0.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DMTK
26
DELISTED
DermTech, Inc. Common Stock
DMTK
| $5.61M | 1.59% |
135,000
+51,000
| +61% | +$2.09M |
|
|
CALY
27
Callaway Golf Company
CALY
$2.65B
| $5.57M | 1.58% |
165,000
+84,000
| +104% | +$2.7M |
|
28
InnovAge Holding
INNV
$1.48B
| $3M | 0.85% |
+141,000
| New | +$3.23M |
|
|
MSACU
29
DELISTED
Medicus Sciences Acquisition Corp. Unit
MSACU
| $2.86M | 0.81% |
296,636
-303,364
| -51% | -$3.09M |
|
30
Centene
CNC
$32.6B
| $2.55M | 0.72% |
+35,000
| New | +$2.4M |
|
|
ISEE
31
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $2.52M | 0.71% |
400,000
-175,000
| -30% | -$1.13M |
|
32
Perrigo
PRGO
$1.88B
| $2.29M | 0.65% |
50,000
+25,000
| +100% | +$1.11M |
|
|
33
Quest Diagnostics
DGX
$27.3B
| $1.98M | 0.56% |
15,000
-135,000
| -90% | -$17.7M |
|
34
PUT
iShares S&P 100 ETF
OEF
$20B
| $1.59M | 0.45% |
5,000
+1,000
| +25% | +$190K |
|
35
Plexus
PLXS
$6.46B
| $1.28M | 0.36% |
14,000
-96,000
| -87% | -$9M |
|
|
CMIIU
36
DELISTED
CM Life Sciences II Inc. Unit
CMIIU
| $673K | 0.19% |
50,000
-50,000
| -50% | -$666K |
|
37
PUT
Abbott
ABT
$177B
| $670K | 0.19% |
+1,000
| New | +$117K |
|
38
Bio-Rad Laboratories Class A
BIO
$10.1B
| $644K | 0.18% |
+1,000
| New | +$609K |
|
|
HOLX
39
CALL
DELISTED
Hologic
HOLX
| $568K | 0.16% |
+2,500
| New | +$167K |
|
40
Cerus
CERS
$510M
| $443K | 0.13% |
75,000
-75,000
| -50% | -$440K |
|
41
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$795B
| $328K | 0.09% |
3,500
+1,400
| +67% | +$584K |
|
|
42
Labcorp
LH
$26.3B
| $276K | 0.08% |
1,164
-86,136
| -99% | -$19.6M |
|
43
CALL
Boston Scientific
BSX
$63.6B
| $258K | 0.07% |
2,000
+1,000
| +100% | +$42.1K |
|
44
CALL
Bristol-Myers Squibb
BMY
$130B
| $245K | 0.07% |
+2,500
| New | +$163K |
|
45
PUT
ARK Genomic Revolution ETF
ARKG
$2B
| $225K | 0.06% |
1,500
-1,500
| -50% | -$128K |
|
46
CALL
Corteva
CTVA
$54B
| $158K | 0.04% |
+1,500
| New | +$69.3K |
|
47
CALL
Pfizer
PFE
$157B
| $84K | 0.02% |
+3,500
| New | +$136K |
|
48
CALL
SPDR Gold Trust
GLD
$144B
| $70K | 0.02% |
5,000
-3,000
| -38% | -$510K |
|
|
MSACW
49
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
| $67K | 0.02% |
+66,665
| New | +$52.8K |
|
50
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$43.5B
| $24K | 0.01% |
+1,500
| New | +$184K |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q2 2021 Portfolio in Review
As of Q2 2021, Tamarack Advisers held 85 positions worth $353M, down 28% from $488M the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Tamarack Advisers withdrew a net $158M in Q2 2021, closing 34 positions and reducing 25 holdings. Its most notable exit was Hologic, an estimated $18.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 87% a quarter earlier, followed by Consumer Staples and Miscellaneous.
Against the trend, Tamarack Advisers opened a new position in Cigna worth $8.3M.
- Tamarack Advisers's largest Q2 2021 buy was Cigna: 35,000 shares worth $8.3M.
- Tamarack Advisers added most to Henry Schein in Q2 2021, an estimated $15.5M increase.
- Tamarack Advisers's biggest Q2 2021 reduction was Labcorp, cutting an estimated $19.6M.
- Tamarack Advisers fully exited Hologic in Q2 2021, selling an estimated $18.4M.
- Tamarack Advisers's ten largest holdings make up 53% of its $353M portfolio in Q2 2021.
- Tamarack Advisers opened 13 new positions and closed 34 in Q2 2021.
- Tamarack Advisers's portfolio value fell 28% quarter-over-quarter to $353M.
Based on Tamarack Advisers's 13F filing for Q2 2021, filed 13 Aug 2021.